Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04294810 · ClinicalTrials.gov registry record · Phase 3
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
NCT04294810 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 620 participants.
The verdict
NCT04294810, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.
Interventions
- DRUG Atezolizumab
- DRUG Matching Placebo
- DRUG Tiragolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04294810
The ClinicalTrials.gov registry entry for NCT04294810 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT04294810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04294810 about?
NCT04294810 is a clinical study titled "A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer". The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth ...
What is the current status of trial NCT04294810?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2020-03-04. Estimated completion is 2025-12-30.
What interventions are being tested in trial NCT04294810?
The interventions under investigation include: Atezolizumab (DRUG), Matching Placebo (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT04294810?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.